TSX Dividend Stocks Featuring Amerigo Resources And Two Others
With Canada's election now behind it, the focus has shifted to economic policies and trade diversification, as policymakers aim to stimulate growth amid a backdrop of softening earnings forecasts. In this environment, dividend stocks can offer stability and income potential for investors seeking resilience; Amerigo Resources and two other TSX-listed companies exemplify this approach with their consistent dividend payouts.
Top 10 Dividend Stocks In Canada
Name
Dividend Yield
Dividend Rating
Royal Bank of Canada (TSX:RY)
3.54%
★★★★★☆
Olympia Financial Group (TSX:OLY)
6.99%
★★★★★☆
Russel Metals (TSX:RUS)
4.11%
★★★★★☆
Savaria (TSX:SIS)
3.00%
★★★★★☆
Whitecap Resources (TSX:WCP)
9.66%
★★★★★☆
Power Corporation of Canada (TSX:POW)
4.35%
★★★★★☆
SECURE Waste Infrastructure (TSX:SES)
3.14%
★★★★★☆
IGM Financial (TSX:IGM)
5.15%
★★★★★☆
Acadian Timber (TSX:ADN)
6.69%
★★★★★☆
Richards Packaging Income Fund (TSX:RPI.UN)
6.11%
★★★★★☆
Click here to see the full list of 25 stocks from our Top TSX Dividend Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Amerigo Resources Ltd., with a market cap of CA$280.60 million, operates through its subsidiary Minera Valle Central S.A. to produce copper and molybdenum concentrates in Chile.
Operations: Amerigo Resources Ltd. generates revenue of $192.77 million from the production of copper concentrates under a tolling agreement with DET.
Dividend Yield: 6.6%
Amerigo Resources' dividend, yielding 6.6%, is among the top 25% in Canada. While dividends have increased, they remain unstable due to a short payment history of four years and volatility. The dividend is well-covered by cash flows (26.6% cash payout ratio) and earnings (71.7% payout ratio). Despite significant insider selling recently, the company reported strong earnings growth with net income rising to US$19.24 million from US$3.38 million year-over-year, suggesting potential for future stability in payouts.
TSX:ARG Dividend History as at May 2025
Simply Wall St Dividend Rating: ★★★★★☆
Overview: Imperial Oil Limited is involved in the exploration, production, and sale of crude oil and natural gas in Canada with a market cap of CA$48.39 billion.
Operations: Imperial Oil's revenue is primarily derived from its Downstream segment at CA$57.32 billion, followed by the Upstream segment at CA$18.31 billion, and the Chemical segment contributing CA$1.40 billion.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Sasol (JSE:SOL) Welcomes New Board Directors Amid Leadership Reshuffle
Sasol recently saw a 38% rise in its share price last month, coinciding with several key developments. The appointment of Ms. Xikongomelo Maluleke as an independent non-executive director and a revised dividend policy, emphasizing sustainable debt management, may have bolstered investor sentiment. Additionally, Sasol's partnership with Henkel on environmentally friendly adhesives aligns with market trends favoring sustainability, potentially appealing to eco-conscious investors. While these company-specific changes added weight, broader market trends, such as optimism over U.S.-China trade talks, also likely contributed to the positive movement in Sasol's shares. You should learn about the 2 risks we've spotted with Sasol. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent appointments and policy revisions at Sasol, alongside its partnership with Henkel, could reinforce the company's focus on cost optimization and environmentally aligned growth strategies, potentially impacting future revenue and earnings positively. These moves, emphasizing renewable energy integration and sustainable debt management, might enhance Sasol's operational efficiency and profit margins over time, supporting the narrative of a strengthened operational framework. Over the past year, Sasol's total shareholder return, including dividends, was a 25.81% decline. Meanwhile, its 12-month price performance shows underperformance compared to both the South African Chemicals industry, which returned a 10.6% decline, and the broader ZA market, which rose 28%. This longer-term perspective underscores the challenges Sasol has faced in navigating market conditions and competitive pressures. While the company's updated initiatives could improve revenue and earnings forecasts, analysts see Sasol's revenue reaching ZAR 269.6 billion, with expectations for substantial earnings growth by June 2028. The share price, currently at ZAR 83.81, remains below the consensus price target of ZAR 118.78, suggesting potential for upward movement if forecasts are met. Investors should consider how these initiatives might align with their expectations and possible industry challenges. Gain insights into Sasol's future direction by reviewing our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include JSE:SOL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
13 minutes ago
- Yahoo
Fortive (NYSE:FTV) Reaffirms Q2 2025 Earnings Guidance of US$0.44-US$0.49 EPS
Fortive recently reaffirmed its earnings guidance for the second quarter of 2025, expecting diluted net earnings per share between $0.44 and $0.49. This stable outlook may have provided some support to their shares, which rose by 4% over the past week. This movement occurred amid broader market gains, aligning with the overall uptrend. As the market climbed 1.5% with anticipation around U.S.-China trade talks and corporate earnings, Fortive's performance seems to have echoed this positive sentiment. Meanwhile, external factors like rising indices may have outweighed any isolated company-specific developments. We've identified 1 warning sign with Fortive and understanding the impact should be part of your investment process. Find companies with promising cash flow potential yet trading below their fair value. The recent reaffirmation of Fortive's earnings guidance appears to have provided some confidence to investors, contributing to the 4% rise in its share price over the past week. This news aligns with broader market movements, as the market increased by 1.5% amid positive sentiments surrounding U.S.-China trade discussions and corporate earnings. Over the past five years, Fortive has achieved a total shareholder return of 38.83%, including both share price appreciation and dividends. This return provides a longer-term perspective, surpassing some expectations within the machinery industry, which had a 9.9% return over the past year, where Fortive underperformed. This latest guidance update may influence future revenue and earnings forecasts positively by reinforcing confidence in Fortive's stability. Analysts are keenly watching how Fortive's separation into New Fortive and Ralliant could unlock further value through targeted strategies. Given the current share price of US$67.25, just under the analyst consensus price target of US$82.86, the company's short-term rise offers a slight discount opportunity. The emphasis on recurring revenue streams and mitigating tariff impacts remains crucial for sustaining profit margins, as the company aims for revenue stability and improved earnings projections nearing US$1.4 billion by 2028. Fortive's ongoing initiatives are expected to impact revenue and margins as they progress towards these targets. The analysis detailed in our Fortive valuation report hints at an inflated share price compared to its estimated value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:FTV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
IQVIA Holdings (NYSE:IQV) Sees 11% Share Price Rise Over Last Week
IQVIA Holdings experienced a 10% rise in share price over the last week, correlating with its recent developments, notably the dosing of the first patient in the RENEW Phase 2 trial and its strategic alliance with Sarah Cannon Research Institute to optimize oncology trials. These initiatives likely provided a positive sentiment boost, aligning well with the broader market momentum, as indices such as the S&P 500 also reached new highs. The market's anticipation over US-China trade talks and overall strong corporate earnings have supported the upward trend, further enhancing IQV's market performance. We've identified 1 warning sign for IQVIA Holdings that you should be aware of. Uncover 18 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent 10% rise in IQVIA Holdings' share price has been influenced by important developments like the dosing in the RENEW Phase 2 trial and a key alliance with Sarah Cannon Research Institute. These initiatives are expected to potentially drive revenue growth, particularly as the strategic alliance optimizes oncology trials. The company's past performance, with total returns of 10.45% over five years, suggests modest growth in investor value. However, compared to the US Life Sciences industry's one-year return of 27% decline, IQVIA's recent rise highlights positive market sentiment. These initiatives, combined with FDA reforms and NVIDIA collaboration, may lower operational costs and have a favorable impact on earnings forecasts. Analysts predict revenue to grow by 5.2% annually over the next three years, which is somewhat cautious compared to the general expectations for the life sciences sector. The recent share price movement to US$146.2 remains below the consensus price target of US$216.31, indicating potential for future appreciation if the projected growth in revenue and earnings materializes. Click here to discover the nuances of IQVIA Holdings with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:IQV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
